Premium
Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G‐CSF in patients with lymphoma
Author(s) -
Zimmerman Todd M.,
Michelson Glenn C.,
Mick Rosemarie,
Grinblatt David L.,
Williams Stephanie F.
Publication year - 1999
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/(sici)1098-1101(1999)14:1<31::aid-jca6>3.0.co;2-c
Subject(s) - medicine , leukapheresis , cyclophosphamide , lymphoma , yield (engineering) , platelet , immunology , chemotherapy , stem cell , genetics , cd34 , biology , materials science , metallurgy
A subgroup of patients with refractory Hodgkin's (HD) or non‐Hodgkin's (NHL) lymphoma may be cured with high‐dose chemotherapy and peripheral blood progenitor cell rescue. To investigate the relationship of adequate leukapheresis yield and time course of platelet recovery after mobilization chemotherapy, we retrospectively analyzed the leukapheresis yields in seven patients with Hodgkin's disease and fifteen patients with non‐Hodgkin's lymphoma undergoing high‐dose chemotherapy. Our goal was to develop a rule to determine when to initiate leukapheresis and then to prospectively validate this rule. All patients were mobilized with cyclophosphamide and G‐CSF (granulocyte‐colony stimulating factor). A total of 144 leukaphereses were completed and analyzed. Based on the CD34 content in the initial harvest product, fifteen patients were defined as poor mobilizers (CD34 < 0.15 × 10 6 /kg) and seven were good mobilizers. The platelet count on the first day of harvesting was significantly associated with the poor mobilizers ( P = .03). Age, sex, marrow involvement, disease (HD vs. NHL), prior radiation, time since last chemotherapy, and total number of cycles of prior chemotherapy were not predictive of poor mobilizers. By using a platelet count cut off of 35 × 10 9 /L, we retrospectively analyzed 144 individual leukapheresis products, to test whether CD34 yield was predicted by the peripheral blood platelet count on the day of leukapheresis. This rule had an excellent sensitivity, 91%, and a specificity of 67%. Subsequently, we validated this rule with the next twenty‐four patients undergoing leukapheresis of which there were 143 leukaphereses. The prediction rule exhibited a sensitivity of 72% and a specificity of 68% in the validation set. There does appear to be utility in using the platelet count to guide the initiation of leukapheresis after chemotherapy and G‐CSF mobilization. J. Clin. Apheresis 14:31–34, 1999.© 1999 Wiley‐Liss, Inc.